Lonza supports development and manufacturing of ABL Bio’s bispecific antibody candidate with a complete and integrated end-to-end solution
New Building at Rockford, Illinois site will significantly increase equipment and capacity for injectable biologics and other self-administered therapies
Company will invest in capacity increases, technological capabilities and long-term partnerships with key pharmaceutical and biotech companies
The new powder flow tester can characterize powder flow properties, offering valuable insight for pharmaceutical processing and formulation
Fluor is providing architectural and engineering services and procuring equipment for the new 275,000 square-foot manufacturing facility that will house two manufacturing lines to double manufacturing capability
The investment enhances Lonza’s capabilities and flexibility to support both clinical and commercial supply and will play a key role in meeting the growing market demand for bioconjugates
India formulation sales at Rs. 3,391.9 crore, up 7.1% over Q3 last year
Sacu V is priced at Rs. 19 per tablet for a dose of 50 mg (sacubitril 24 mg + valsartan 26 mg)
New facility is based at Lonza’s Bend, Oregon (US) site, a Center of Excellence for bioavailability enhancement
Biocytogen will provide a license to Hansoh Pharma for their selected fully human antibody molecules
Subscribe To Our Newsletter & Stay Updated
